Progyny (PGNY) EBITDA (2018 - 2026)

Progyny (PGNY) has 9 years of EBITDA data on file, last reported at $35.4 million in Q1 2026.

• On a quarterly basis, EBITDA rose 46.38% year-over-year to $35.4 million in Q1 2026; TTM through Mar 2026 was $96.5 million, a 31.99% increase from a year earlier, with the FY2025 full-year figure at $85.3 million, up 26.42% from the prior year.
• EBITDA for Q1 2026 stood at $35.4 million, up from $15.2 million in the prior quarter.
• Over the last five years, EBITDA for PGNY reached as high as $35.4 million in Q1 2026 and fell as low as -$58000.0 in Q1 2022.
• Historically, EBITDA has averaged $16.1 million across 5 years, with a median of $15.2 million in 2025.
• Across the five-year window, EBITDA tumbled 100.49% in 2022 and soared 25981.03% in 2023, its largest moves.
• Year by year, EBITDA stood at $3.3 million in 2022, then soared by 317.42% to $13.8 million in 2023, then grew by 14.4% to $15.8 million in 2024, then retreated by 3.58% to $15.2 million in 2025, then soared by 132.42% to $35.4 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $35.4 million in Q1 2026, $15.2 million in Q4 2025, and $21.5 million in Q3 2025.